PHARMACOR SITAGLIPTIN (Pharmacor Pty Ltd)
Product name
PHARMACOR SITAGLIPTIN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
114 (255 working days)
Active ingredients
sitagliptin hydrochloride monohydrate
Registration type
New generic medicine
Indication
PHARMACOR SITAGLIPTIN is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as:
- monotherapy when metformin is considered inappropriate due to intolerance; or
- in combination with other anti-hyperglycaemic agents, including insulin